GlobeNewsWire
31 Mar 2026, 23:39 UTC · 25w ago
Verdict
Headline leans bearish. We score QURE −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
An FDA official reportedly called uniQure's lead gene therapy candidate, AMT-130, a 'failed therapy' and accused the company of using a 'distorted or manipulated comparison' rather than a correct clinical study.
So whatDirect negative feedback from the primary regulator regarding a lead product candidate typically leads to severe devaluation of a biotech company's pipeline and stock price.
More negative than 99% of claims this week
A securities class action lawsuit alleges uniQure misrepresented its interactions with the FDA and used a pivotal study design that the agency had not approved.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 95% of claims this week
Law firm Hagens Berman is updating its investigation into uniQure and reminding investors of the April 13, 2026, deadline to apply as Lead Plaintiff in the pending class action.
More negative than 70% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities class action lawsuit and severe rebukes from the FDA alleging manipulated data and a failed therapy candidate.
More negative than 85% of ticker scores this week
Mentioned as having a plunging stock price due to allegedly misleading financial statements.
More negative than 85% of ticker scores this week
Mentioned as having a plunging stock price due to allegedly misleading financial statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
+134.4%
Price is moving against the score
$38.32 vs $16.35 close before publication (Mar 31) · not market-adjusted
QURE chart →
